Table 3 Distribution of neurological disorders among vaccinated groups
Neurological disorders (n = 283) | COVID-19 vaccine | p value | ||||
|---|---|---|---|---|---|---|
AstraZeneca (n = 155) | Johnson (n = 6) | Pfizer (n = 19) | Sinovac (n = 37) | Sinopharm (n = 66 | ||
No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | ||
Vascular disease | 82 (52.9%) | 5 (83.3%) | 9 (47.4%) | 21 (56.8%) | 35 (53%) | 0.6 |
Autoimmune related diseases | 26 (16.8%) | 1 (16.7%) | 3 (15.8%) | 6 (16.2%) | 10 (15.2%) | |
Paroxysmal disorders | 39 (25.2%) | 0 (0%) | 6 (31.6%) | 10 (27%) | 16 (24.2%) | |
Headache | 5 (3.2%) | 0 (0%) | 1 (5.3%) | 0 (0%) | 3 (4.5%) | |
Others | 3 (1.9%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (3%) | |